Since Alzheimer Europe started its work, it has completed 16 projects. Currently, the organisation is involved in the following projects:
National Dementia Strategies
- to identify the medical and scientific issues included in each national dementia plan in order to enable a comparison of the different plans.
- to provide an overview of other regulations or instruments which address these issues, including countries which do not yet have a dementia plan.
- to provide an overview of whether, and if so how, each country addresses the range of medical and scientific issues identified collectively in the dementia plans.
The Dementia Monitor - an Alzheimer Europe project - aims to be a European benchmark of national dementia policies. It will be based on data provided by AE's member associations and pharmaceutical partners. This is the first time these two groups work together on such a project. The Dementia Monitor will be useful for presenting comparative data to the European Parliament and European Commission. In addition, national organisations can use it to compare their situation to that of other European countries. Alzheimer Europe will compile and develop the final report, which will be presented at a lunch debate in the European Parliament in December 2013.
Good Incontinence Care working group
The project on “good incontinence care for people with dementia ” began in March 2013. Alzheimer Europe and SCA Global Hygiene are working together to develop guidelines for incontinence care of people with dementia, particularly in the home care setting. They will explore issues such as the prevalence of incontinence and dementia in the home setting, access to incontinence care, the training of carers, ethical issues, assessment and diagnosis . The project will conclude in October 2014, with the presentation of the results at Alzheimer Europe’s annual conference in Glasgow. This project is fully funded by SCA Global Hygiene.
The Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development (PharmaCog) is a project which was started at the beginning of 2010 thanks to significant funding (EUR 20.2 million) from the Innovative Medicines Initiative. It aims to tackle bottlenecks in Alzheimer’s disease research and drug discovery. We are collaborating on this project alongside representatives from 31 academic institutions, global pharmaceutical companies and small and medium enterprises.
Led by Trinity College, Dublin, NILVAD is an international research consortium which is conducting a clinical trial of the drug nilvadipine for Alzheimer's disease. The five year project has been awarded EUR 6 million by the European Commission. The consortium is comprised of 17 partners, including universities, hospitals, pharmaceutical companies and Alzheimer Europe.
This five year project aims to develop a common information framework of patient-level data, with an initial focus on Alzheimer’s disease and obesity. The project began in January 2013 and intends to facilitate access to existing data sources, ease the creation of links between sources and collect additional information wherever needed. The project partners will address such issues as data standards, interoperability, data privacy and ethical and legal issues. They will also cooperate to leverage “tranSMART”, an IT platform that allows access to multiple data sources. The EMIF project has received support from EFPIA companies and the European Union (IMI JU).
Last Updated: lundi 08 juillet 2013